The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Andrew E. Tee 1 , Dora Ling 1 , Charlotte Nelson 1 , Bernard Atmadibrata 1 , Marcel E. Dinger 2 , Ning Xu 1 , Tamio Mizukami 3 , Pei Y. Liu 1 , Bing Liu 1 , Belamy Cheung 1 , Eddy Pasquier 1,4 , Michelle Haber 1 , Murray D. Norris 1 , Takayoshi Suzuki 5 , Glenn M. Marshall 1,6 and Tao Liu 1,7 1 Children’s Cancer Institute Australia for Medical Research, Randwick, Sydney, Australia 2 Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia 3 Graduate School of Bio-Science, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, Japan 4 Metronomics Global Health Initiative, Marseille, France 5 Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Taishogun Nishitakatsukasa-Cho, Kita-ku, Kyoto, Japan 6 Kids Cancer Centre, Sydney Children’s Hospital, Randwick, , Australia 7 School of Women’s & Children’s Health, UNSW Medicine, University of New South Wales, Randwick, Sydney, Australia Correspondence: Tao Liu, email: // Keywords : neuroblastoma, N-Myc, JMJD1A, histone demethylation, MALAT1 Received : January 3, 2014 Accepted : February 16, 2014 Published : February 18, 2014 Abstract Patients with neuroblastoma due to N-Myc oncogene amplification have a high frequency of tumor metastasis. However, it is not clear how N-Myc induces cell migration, invasion and metastasis. The histone demethylase JMJD1A activates gene transcription by demethylating the lysine 9 residue of histone H3 (H3K9) at target gene promoters. The long noncoding RNA MALAT1 induces lung cancer cell migration and plays a pivotal role in lung cancer metastasis. Here we demonstrated that N-Myc up-regulated the expression of JMJD1A in N-Myc oncogene-amplified human neuroblastoma cells by directly binding to the JMJD1A gene promoter. Affymetrix microarray studies revealed that the gene second most significantly up-regulated by JMJD1A was MALAT1. Consistent with this finding, RT-PCR and chromatin immunoprecipitation assays showed that JMJD1A bound to the MALAT1 gene promoter and demethylated histone H3K9 at the MALAT1 gene promoter. Moreover, JMJD1A and MALAT1 induced, while the small molecule JMJD1A inhibitor DMOG suppressed, neuroblastoma cell migration and invasion. Taken together, our data identify a novel pathway through which N-Myc causes neuroblastoma cell migration and invasion, and provide important evidence for further development of more potent JMJD1A/MALAT1 inhibitors for the prevention of tumor metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“Histone deacetylase inhibitors are among the most promising novel anticancer agents [35], and have been approved by US Food and Drug Administration for cancer therapy.”
BackgroundReflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 1×
“Myc oncoproteins, including N-Myc and c-Myc, induce malignant transformation and tumor progression by directly binding to cognate DNA sequences and modulating gene transcription [3, 4].”
BackgroundEilers, M., & Eisenman, R. N. (2008) · Genes & Development · doi:10.1101/gad.1712408 · Cited by 927
Krieg, A. J., Rankin, E. B., Chan, D., Razorenova, O., Fernandez, S., & Giaccia, A. J. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00444-09 · Cited by 334 · cited 3×
“JMJD1A has been well documented to induce tumor progression by up-regulating HIF1α expression and stimulating angiogenesis [16, 18, 20, 27].”
BackgroundResult
Cited by
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Long Non-Coding RNA in the Pathogenesis of Cancers
Chi, Y., Wang, D., Wang, J., Yu, W., & Yang, J. (2019) · Cells · doi:10.3390/cells8091015 · Cited by 791
The long noncoding RNA Malat1: Its physiological and pathophysiological functions
Zhang, X., Hamblin, M. H., & Yin, K.-J. (2017) · RNA Biology · doi:10.1080/15476286.2017.1358347 · Cited by 482
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
Amodio, N., Raimondi, L., Juli, G., Stamato, M. A., Caracciolo, D., Tagliaferri, P., & Tassone, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0606-4 · Cited by 348
MALAT1 Long Non-Coding RNA: Functional Implications
Arun, G., Aggarwal, D., & Spector, D. L. (2020) · Non-Coding RNA · doi:10.3390/ncrna6020022 · Cited by 276
Xu, S., Fan, L., Jeon, H.-Y., Zhang, F., Cui, X., Mickle, M. B., Peng, G., Hussain, A., Fazli, L., Gleave, M. E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0233 · Cited by 64
MALAT1: A long non‑coding RNA highly associated with human cancers (Review)
Zhao, M., Wang, S., Li, Q., Ji, Q., Guo, P., & Liu, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.8613 · Cited by 32
Metadata
- Authors
- Tee, A. E., Ling, D., Nelson, C., Atmadibrata, B., Dinger, M. E., Xu, N., Mizukami, T., Liu, P. Y., Liu, B., Cheung, B., Pasquier, E., Haber, M., Norris, M. D., Suzuki, T., Marshall, G. M., & Liu, T.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-02-18
- Volume
- 5
- Issue
- 7
- Pages
- 1793-1804
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1490872766
- Cited by
- 119
- References
- 5
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.